CHALLENGES AND OPPORTUNITIES IN REGULATORY AFFAIRS: BIOTHERAPEUTICS, BIOLOGICS, BIOSIMILARS AND BIOBETTERS.

B. Pharmacy

A shortened Food and Drug Administration approval process for biosimilar medicines that are more affordable and very comparable to the reference biological product but not identical. Fewer biosimilars are anticipated to enter the biologics industry than generic pharmaceuticals did when they first entered the small-molecule medication market since bringing biosimilars to market currently demands large financial commitments. Furthermore, subject to changing state substitution laws, most biosimilars will likely compete as therapeutic alternatives rather than as therapeutic equivalents due to the high regulatory hurdles to obtaining interchangeability, which would allow pharmacists to substitute a biosimilar for its reference product. In other words, in order to compete with their reference product, biosimilars must offer superior quality, lower prices, and a producer with a solid reputation among medical professionals, insurers, and patient groups. The development of novel biologics in the same therapeutic class, such as "biobetters," which provide minor upgrades over reference medicines like a longer duration of action, will also pose a significant threat to the viability of biosimilars. For the foreseeable future, it seems like there won't be many large cost savings from using biosimilars, but supply and demand-side variables should eventually lead to a rise in their utilization.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.